GlassScriptPhysician profile
Vincent J Trapanotto
NPI 1871570465
$4,661.32
in general payments reported to CMS, 2019-2025
29 companies · $1,532 in 2025
The $1,532 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $57.16 · 2021: $211 · 2022: $504 · 2023: $991 · 2024: $1,217 · 2025: $1,532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,739.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,178.96 | 2022-2025 | Injectafer |
| Abbvie INC. | $940.39 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $579.44 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $391.08 | 2019-2025 | |
| Abbott Laboratories | $195.10 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $182.83 | 2022-2025 | Otezla, Repatha, Repatha |
| Glaxosmithkline, LLC. | $182.33 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $158.35 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $142.78 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Exact Sciences Corporation | $126.67 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $80.46 | 2024-2025 | Austedo Xr, Austedo Xr |
| Astellas Pharma US INC | $70.88 | 2022-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $66.97 | 2024-2025 | Rexulti |
| Alkermes, INC. | $39.30 | 2022-2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $38.91 | 2022-2024 | Xarelto |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $37.39 | 2024 | Aptiom |
| E.R. Squibb & Sons, L.L.C. | $34.99 | 2023-2025 | Eliquis |
| Sunovion Pharmaceuticals INC. | $29.76 | 2021-2022 | |
| Edwards Lifesciences Corporation | $25.31 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Lundbeck LLC | $21.90 | 2025 | Rexulti |
| Acadia Pharmaceuticals INC | $20.60 | 2025 | Nuplazid |
| Dexcom, INC. | $17.84 | 2023 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $17.22 | 2024 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.23 | 2023 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $14.38 | 2023 | |
| Novartis Pharmaceuticals Corporation | $14.30 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.14 | 2022 | |
| Radius Health, INC. | $12.00 | 2019 | |
| Allergan, INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Trapanotto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.